Engineered immune cells take on childhood cancer in early trial

This early-stage trial tests a new treatment called GD2 CAR T cells in 12 children and teens (ages 1-16) with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack the cancer, and giving them back. The main goals are to see if the cells can be made safely and to check for serious side effects.